HIT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Health In Tech Inc (HIT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown significant revenue growth and improved net income, the technical indicators suggest a bearish trend, and there are no strong proprietary trading signals or recent insider/congressional activity to support an immediate buy decision. Additionally, the stock's recent PIPE financing, while positive for long-term growth, introduces dilution risks in the short term. It is better to hold off for now and monitor the stock for more favorable entry points.
The technical indicators show a bearish trend. The MACD is below 0 and negatively contracting, the RSI is neutral at 37.937, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.6, with key support at 1.302 and resistance at 1.898.
The company recently closed a $7 million PIPE financing to support platform development, expand sales distribution, and advance technology development. This introduces long-term institutional investors, enhancing market visibility.
The PIPE financing dilutes existing equity, which may weigh on the stock price in the short term. Additionally, gross margin dropped significantly by 28.98% YoY in Q4 2025.
In Q4 2025, revenue increased by 53.09% YoY to $7,508,585, and net income improved by 109.89% YoY to -$302,557. However, gross margin dropped to 54.99%, down 28.98% YoY, and EPS remained flat at -0.01.
Maxim recently lowered the price target from $4.50 to $4, maintaining a Buy rating. The adjustment reflects the company's Q4 results and dilution from the recent equity raise.
